servier.com
May 24, 2025, 09:33
Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals
Servier shared a post on LinkedIn:
“We are thrilled to announce that we have acquired a precision therapy with the potential to be ‘best-in-class’ for acute leukemias from BioNova Pharmaceuticals. This acquisition strengthens our leadership in blood cancer and commitment to developing precision medicine in line with our 2030 strategy. At Servier, we have made oncology one of our priority innovation areas. We invest close to 70% of our R&D budget in oncology, with a view to becoming a focused and innovative player in rare cancer treatments.”
More posts featuring Servier.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 27, 2025, 14:04
Jul 27, 2025, 13:56
Jul 27, 2025, 13:48
Jul 27, 2025, 13:42
Jul 27, 2025, 13:03
Jul 27, 2025, 07:35
Jul 27, 2025, 06:56